Re-analysis of cancer vaccine patients with immune-related clinical response criteria (iRRC)

Kentaro Nishida, Takuro Saito, Shinya Urakawa, Masaki Mori, Kazuhiro Kakimi, Yuichiro Doki, Hisashi Wada

研究成果: Contribution to journalArticle査読

抄録

Anti-tumor responses induced by immunotherapy such as cancer vaccine are presumed to be mediated by induction of cancer-specific immune responses. Therefore, the immune-related response criteria (irRC) have been applied for cancer immunotherapies instead of the Response Evaluation Criteria in Solid Tumors (RECIST). Clinical responses of 91 patients enrolled in our cancer vaccine clinical studies were evaluated using RECIST. In this study, we re-analyzed their clinical responses using irRC. We identified 2 patients whose responses were evaluated as PD by RECIST, but as PR and SD by irRC, respectively. As these 2 patients showed relatively long survival rate, we concluded that irRC was suitable for the assessment of clinical outcomes in cancer immunotherapy.

本文言語英語
ページ(範囲)1466-1468
ページ数3
ジャーナルJapanese Journal of Cancer and Chemotherapy
45
10
出版ステータス出版済み - 10 2018
外部発表はい

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

フィンガープリント 「Re-analysis of cancer vaccine patients with immune-related clinical response criteria (iRRC)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル